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The influence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and the recently identi-
fied hematopoietic stem-progenitor cell mobilizing 
factor flt3 ligand (FL) on donor leukocyte microchi-
merism in noncytodepleted recipients of allogeneic 
bone marrow (BM) was compared. BI0 mice (H2b ) 
given 50XI06 allogeneic (BlO.BR [H2k]) BM cells also 
received either GM-CSF (4 "g/day s.c.), FL (10 "g/day 
i.p.), or no cytokine, with or without concomitant ta-
crolimus (formerly FK506j 2 mg/kg) from day O. Chi-
merism was quantitated in the spleen 7 days after 
transplantation by both polymerase chain reaction 
(donor DNA [major histocompatibility complex class 
II; I_Ek]) and immunohistochemical (donor [I·Ek+] cell) 
analyses. Whereas GM-CSF alone significantly aug-
mented (fivefold) the level of donor DNA in recipients' 
spleens, FL alone caused a significant (60%) reduction. 
Donor DNA was increased lO-fold by tacrolimus alone, 
whereas coadministration of GM-CSF and tacrolimus 
resulted in a greater than additive effect (28·fold in-
crease). A much more striking effect was observed 
with FL + tacrolimus (> 125-fold increase in donor 
DNA compared with BM alonel. These findings were 
reflected in the relative numbers of donor major his-
tocompatibility complex class 11+ cells (many resem-
bling dendritic cells) detected in spleens, although 
quantitative differences among the groups were less 
pronounced. Evaluation of cytotoxic T lymphocyte 
generation by BM recipients' spleen cells revealed 
that FL alone augmented antidonor immunity and 
that this was reversed by tacrolimus. Thus. although 
FL may potentiate antidonor reactivity in nonimmu-
nosuppressed. allogeneic BM recipients. it exhibits po-
tpnt chimerism-enhancing activity when coadminis-
t'-"ed with l'ecipient immunosuppressive therapy. 
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This property of FL may offer considerable potential 
for the augmentation of microchimerism, with thera-
peutic implications for organ allograft survival and 
tolerance induction. 
In organ allograft recipients, the persistence of donor leu-
kocytes within recipient tissues for indefinite periods has 
been construed as evidence of the transfer of hematopoietic 
stem and progenitor cells (1,2). Moreover, multiline age do-
nor leukocyte microchimerism has been postulated to be an 
essential condition for organ allograft acceptance (1-3). Ac-
counts of the multilineage nature of microchimerism have 
emphasized the invariable prominence of donor-derived den-
dritic cells (DC*) (1-5). Both DC progenitors and other leu-
kocytes of donor origin that engage the host immune system 
may have tolerogenic properties (6l. 
Current efforts to enhance "spontaneous microchimerism" 
in human organ transplantation focus on the administration 
of unmodified donor bone marrow (BMl by either single or 
multiple infusions (7, 8). This is undertaken without recipi-
ent cytoablation. Conventional immunosuppressive therapy 
is believed to facilitate donor cell survival and to promote the 
reciprocal donor-recipient leukocyte engagement that may 
provide the basis of allograft acceptance (9). A potential chi-
merism-enhancing strategy that is well-recognized in BM 
transplantation. but that has not been evaluated formally in 
organ allograft recipients, is the use of hematopoietic growth 
factors. Many of these can either enhance, inhibit, or bi-
functionally affect the proliferation and differentiation of 
hematopoietic progenitor cells (1O-J:1). They comprise gran-
ulocyte-macrophage colony-stimulating factor (GM-CSFl, 
granulocyte colony-stimulating factor l G-CSFl, and a variety 
of other cytokines that act at an earlier point in the hemato-
poietic cascade, such as Interleukin I ILl 3, stem cell factor 
I c-kit ligand J. and the recently cloned flt3 ligand (FLl (14). 
In the hemopoietic sYstem, the expression of flt3 (a mem-
Abbrevwtions: B:\r. bone marrow: t ·TL. c.vtotoxic T Iymphocvte: 
DC. dendritic cell: FL. tlt3 lil;and: G-CSF. h'Tanuiocyte colonv-stlm-
ldatrnC' 1:1ctor: t }:-'I-C'SF. granulocyte-macrophage colonv-stlmulat-
11lC' bctor: IL. interleukin: .\IHC: rn;110r hlstocompatlbilitv complex: 
I'BS. phosphate-hullerpd salrne: peR: polvmerase charn reaction. 
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ber of the type III receptor tyrosine kinase family that also 
includes c-kit and fms) is believed to be restricted to primitive 
progenitor cells that respond to FL (]4-17). FL potently 
synergizes with the colony-stimulating factors and c-kit li-
gand to enhance growth of hemopoietic progenitors 114 -19). 
Notably, there is recent evidence that in contrast to the case 
with GM-CSF, G-CSF, and c-kit ligand, administration of FL 
to normal mice leads to dramatic increases in DC numbers, 
both in lymphoid and nonlymphoid tissues (20), In this study, 
we examined the influence of short-term (7-day) FL treat-
ment on donor leukocyte microchimerism, both in normal 
(noncytoablated) and tacrolimus (formerly FK506)-immuno-
suppressed recipients of unmodified allogeneic BM. For com-
parative purposes, similar experiments were undertaken 
with GM-CSF. The results show that when administered 
with tacrolimus, FL dramatically augments hematopoietic 
cell chimerism within recipient lymphoid tissue. We also 
show that donor major histocompatibility complex (MHC) 
class I1+ cells with distinct DC characteristics are a promi-
nent feature of the greatly enhanced donor cell population. 
These findings may have important implications for the ther-
apeutic application of FL to augment chimerism and to pro-
mote donor-recipient leukocyte interactions that may predis-
pose to improved organ allograft survival. 
MATERIALS AND METHODS 
Animals. B10.BR <H2k, I_Ek), C57BUI0J (B10; H2b , I-Ab), and 
C3H <H2k; I-Ek) mice, 6-12 weeks old, were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and maintained in the central 
specific pathogen-free facility of the lJ niversity of Pittsburgh Medical 
Center. 
Cytokines and tacrolimus. Recombinant mouse GM-CSF pro-
duced in Escherichia coli was a gift from Dr. S.K. Narula, Schering-
Plough Research Institute, Kenilworth, NJ. Chinese hamster ovary 
cell-derived human FL (2]) was kindly provided by Dr. H.J. McK-
enna. Immunex Research and Development Corp., Seattle. WA. GM-
CSF (4 /J.g/day s.c.) or FL (10 J.Lglday i. p.) was injected in 0.1 ml of 
low-endotoxin phosphate-buffered saline (PBS). Control mice re-
ceived PBS alone. Tacrolimus (FK506) was obtained from the Fuji-
sawa Pharmaceutical Co .. Osaka, Japan, in powder form and in-
jected intraperitoneally (2 mg/kgJ in suspension in 0.5 ml of PBS on 
days 0, 2, 4, and 6 (experiment 1) or days 0-6 (experiment 2), 
Treatment protocols. BM transplantation was performed using 
both the BlO.BR .... BID and BIO-C3H combinations. Recipient mice 
1 four per group) were given intravenous injections of 50x lOti freshly 
isolated. unmodified donor BM cells in RPMI 1640 (Life Technolo-
;.,>ies. Grand Island, NY) via the lateral tail vein. In addition, they 
received either GM-CSF lexperiment 11. FL (experiment 2). or no 
cytokine. with or without tacrolimus for 7 consecutive days, starting 
at the time of BM transplant 1 day 0 I. On day 7. the animals were 
killed by cervical dislocation. Splet'ns wpre harvested for analysis. 
DNA extraction. Freshl.v isolated. monodispersed spleen cell Iy-
sates were treated with pancreatlc rIhonuclease as described 1:221. 
and whole genomic DNA was extracted usinp; a DNA extractIOn kit 
,qiap;en. Studio Citv. (',\ I. The DNA was quantitated bv ultraviolet 
spectroscopy. and was at least 40 kb lonp;, indicatmg that it was 
derivl'd from Intact cells. The concentration of the p;enomlc DNA was 
measured bv spectrophotometrv at :!()O and :!HO nm. This WaS v"n-
lied llsing low-voltage gel l'lectrophorl'SIS and l'thldium hromlde 
fluorescence ,::::1 With sub6equt'nt densltometrtc standardization. 
«(/lalll/lallOll Of donor D,VA hv jJu/vlI/cra" .. ('halll ",·al'llOll. ()[il(o-
nucleotldes 1(11' the dl'tect\on of donor :\IHC da,;s l! allele-specl!ic 
DNA iI-E'1 in lEO l'l'clplents of B IO.BR 13;"1 w{'rt' l'Ustom-made at 
(1Iil(oS Etc. Inc .. \\·ilsonvlill'. (Ill. TIll' st'queIlCl'S 01 till' !(Irward and 
,<,verse pruners wt'n' ;;' -ATT(;,\(;(;( '('I ;,\( .( 'A( .( ;T.\(il'T :1' .lnd :i'-
ACCTTGGGGCTCAAA TCTTCT 3'. respectively. The primers were 
designed to distinguish donor DNA from recipient DNA and yielded 
no visible polymerase chain reaction (PCR) product of 160 bp with 
recipient DNA template under ethidium bromide fluorescence. or a 
detectable product using an oligomer probe Southern blot. Using 
these allele-specific PCR prtmers and the target DNA from the B\! 
transplant recipients. amplification was carried out using reager' , 
from Perkin Elmer Inc .. Norwalk, CT. under standard conditions \ 
series of reactions varying in cycling parameters alone were pt-
formed with 32p-dCTP and 27 thermal cycles and found to be optimal 
over a range of 100 pg to 100 ng of donor DNA. The yield of radio-
labeled PCR product from the unknown samples was measured by 
densitometric analysis with donor DNA as positive control DNA. 
PCR product yield of donor DNA template used as positive control in 
the experiments with the unknown samples was comparable to the 
standards. This served to calculate the amount of donor DNA in the 
unknown composite DNA samples. The semiquantitative assess-
ment was further verified by a limiting dilution PCR assay (231. 
Briefly, varying dilutions of reference DNA were diluted serially to 
derive the dilution that yielded a qualitative yes-orono reaction. 
Donor DNA in the unknown samples was quantitated by the degree 
of dilution necessary to replicate three to five positive events in 10 
reactions. The previously mentioned semiquantitative analysis W'-
ing 32p_dCTP served as a guideline for the latter exhaustive anah 
ses. All enzyme assays were performed three times to check fll' 
reproducibility. Results of the different donor template quantitative 
reactions were expressed as amounts of donor DNA per microgram of 
total composite DNA. 
Immunohistochemistry. Cryostat sections of spleen from B10 re-
cipients ofB10.BR EM were equilibrated at room temperature, fixed 
in acetone, and stained for donor MHC class II using biotinylated 
mouse IgG2a anti-mouse I_Ek.d.p.r (PharMingen, San Diego, CAl in 
an avidin-biotin-peroxidase staining procedure, as described previ-
ously (24), Controls included sections of normal donor or recipient 
strain tissue. The incidence of donor MHC class n+ cells in sections 
was determined by two blinded observers. The results are expressed 
as the mean number of positive cells per 60 high-power fields. 
Cell-mediated lymphocytotoxicity assay. Freshly isolated spleen 
cells obtained from C3H recipients of B10 BM 7 days after trans-
plantation were used as effectors. They were restimulated in vitro for 
5 days with gamma-irradiated 120 Gy) donor strain splenocytes. The 
EL4 (H2b ) mouse lymphoma cell line (TIB39; American Type Culture 
Collection IATCC]. Rockville. MOl was used as a source of specific 
target cells. The P815 (H2d ) mouse mastocytoma cell line ,TIB64; 
ATCC) and the Rl.l (H2k11ymphoma cell line (TIB42; ATCC) were 
used as third-party and syngeneic targets, respectively. The target 
cells were labeled with 100 J.LCi of Na2,;lCrO. (NEN. Boston. MAl. 
washed, and plated at a concentration of 5X 103 cells/well in 96-well 
round-bottomed culture plates (Corning, Coming, NYl. Serial. two-
fold dilutions of effector cells were added to give effector to target 
ratios of 50: 1. 25: 1, and 12.5:1 in a total volume of 200 J.LlIwell. The 
percentage of specific "'Cr release was determined after the plates 
were incubated for 4 hr at 37°C in 5',1 Cl~ in air. The supernatant 
was recovered from each well using a supernatant collection system 
(Skatron Inc .. Sterling, VAl. Maximum ';!Cr release was determined 
bv osmotic lysis of the cells. The percent specific cytotoxicitv was 
calculated lf~mp; the !t,llowlnp; !(Irmula: (; evtotoxicitv 100' it'x· 
iJ<'nm(,lIlni (cpm) '1)(",talll'''IlS Icpm )/lI1nnmum (cpm) -'polllnlle· 
"US Icpmd. The I'l'sults are t'xpn'ssed as mean::':: ISD of perCl'nt 
specliic :"('r I'pleasp III t l'Iplicatl' cultures. 
Slatlsl/c.'. The slgnt!icance <Ii' ditlerpnces between means was de-
(ermmpd llSIIll( til!' nonparaml'tl'lc :\lann-Whitney lJ test. 
ImSl:LTS 
[lItlUL'llc'c' til(;.H-('SFa[lll/C' or III ('ol1lhillatwn u'lth t([croit-
1)11/8 Oil /1'['('i" Of cim/o/' f),VA Ef·/~"··F ill aliogenC'lc nJI I'I'C·IPI1'III". 
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Recombinant mouse GM-CSF has been shown to enhance 
hematopoietic reconstitution after syngeneic or allogeneic 
BM transplantation in lethally irradiated mice (25,26). Al-
ternatively, ex vivo preincubation of donor marrow cells with 
recombinant mouse GM-CSF significantly improves the seed-
ing efficiency of hematopoietic stem cells and other progeni-
tor cells after transplantation to irradiated recipients (25, 
27). In view ofthese findings, we determined the influence of 
recombinant mouse GM-CSF (administered daily) on the 
level of micro chimerism (donor DNA) within lymphoid tissue 
(spleen) of normal (noncytodepleted) and tacrolimus-treated 
BI0 (H2b ) mice given 50x106 allogeneic (BI0.BR [H2k]) BM 
cells 7 days earlier. The results of quantitative PCR analysis 
for donor DNA (MHC class II; I-Ek) are shown in Table 1. 
Both GM-CSF and, to a greater extent, tacrolimus markedly 
increased the level of chimerism (5- and 10-fold, respectively) 
compared with that achieved with BM transplantation alone. 
When GM-CSF and tacrolimus were combined, however, a 
greater than additive effect was achieved, with almost 30 
times the level of donor DNA detected compared with BM 
alone. 
Influence of FL alone or in combination with tacrolimus on 
levels of donor DNA (/_Ek) in allogeneic BM recipients. In a 
separate experiment, using the same strain combination, FL 
was substituted for GM-CSF, and its influence on the level of 
donor DNA was determined. In contrast to the effect of GM-
CSF, daily administration ofFL significantly reduced (to less 
than 40%) the level of DNA encoding donor MHC class II 
within the spleen compared with mice given BM alone (Table 
2). The level of donor DNA in mice given both FL and tacroli-
mus, however, was increased dramatically compared with 
that in either untreated or FL-treated animals (more than 
120-fold and 300-fold, respectively). It was 10-fold greater 
than that observed in mice given tacrolimus alone. The level 
of chimerism in tacrolimus-immunosuppressed mice was 
fourfold greater in those also given FL compared with those 
al!'o given GM-CSF. Since the total number of nucleated 
spleen cells in FL-treated mice was markedly increased com-
pared with that in animals given BM alone (FL: 4.7-fold, 
FL+tacrolimus: 3.8-fold; Table 3), the increase in absolute 
numbers of donor cells in immunosuppressed. FL-treated 
animals was substantial. 
Effects o(GI'"J·CSF and FL on donor MHC class Ir cells in 
normal and immunosuppressed recipients. Cryostat sections 
of spleen from each mouse in each of the above experimental 
groups were stained using monoclonal antibody against do-
nor MHC class 11 (l-Ek+l. The mean number of chimeric 
leukocytes per unit area (60 high-power fields) was deter-
mined. The results (Table 4) showed a pattern similar to that 
obtained by molecular (PCR) analysis, although the quanti-
tative difference in the numbers of donor cells among the 
groups was less than that observed by DNA quantitation. 
Nevertheless. the immunohistochemical data indicated a rel-
ative 35-fold increase in the number of donor class II+ cells in 
mice treated with FL + tacrolimus compared with those 
given BM alone. Interestingly, the data confirmed that FL 
administration alone reduced the number of donor cells sur-
viving within recipient lymphoid tissue, even when the fact 
that this cytokine significantly increased the total number of 
nucleated spleen cells was taken into account. The appear-
ance of typical, donor MHC class II+ cells is shown in Figure 
1. Many of these "chimeric" cells displayed DC characteristics 
and were present both in T cell and other areas ofthe spleen. 
Effects of FL and tacrolimus on antidonor cytotoxic T lym· 
phocyte responses. To ascertain the possible functional (im-
munologic) significance of the changes in donor cell numbers 
induced by FL and tacrolimus, antidonor cytotoxic T lympho-
cyte (CTL) responses of spleen cells from allogeneic BM re-
cipients were examined 7 days after transplantation. Using 
the BI0 to C3H (H2b .... H2k) strain combination, it was ob-
served that, compared with allogeneic BM alone, FL treat-
ment significantly augmented the generation of antidonor 
CTL activity. The combination of FL and tacrolimus, how-
ever, resulted in reduced antidonor cytotoxicity compared 
with that seen with cells from either untreated mice or mice 
treated with tacrolimus alone (Fig. 2). 
DISCUSSION 
Hematopoietic cell chimerism occurs in recipients of organ 
allografts and is persistent and long-lasting in those animals 
and humans that accept their grafts with or without the need 
for immunosuppressive therapy. Thus, we have shown pre-
viously that donor-derived progenitor cells (DCs) can be prop-
agated from the BM of "spontaneously" tolerant organ (liver) 
allograft recipients, but not from those that reject (cardiac) 
transplants from the same donor strain (28). These findings 
implied that an organ (the liver) with a relatively large 
constituency of progenitor and stem cells was more likely to 
be accepted than one (the heart) with only a paucity of "pas-
senger leukocytes." Related studies in noncytoablated, ta-
crolimus-immunosuppressed recipients of whole organ or BM 
transplants have shown that tissue chimerism is closely as-
sociated with tolerogenicity (29l. 
There is now considerable interest in the clinical use of 
donor BM to augment leukocyte microchimerism in conven-
tionally immunosuppressed organ allograft recipients. An 
alternative/additional approach is the use (either alone or 
together with donor BM) of hematopoietic cytokines that 
T,\HLE 1. Influence of GM·CSF and tacrolimus on levels of donor DNA t I·Ek ) in spleens of allogeneic 13M recipients" I('xperiment 1 I 
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TABLE 2. Influence of FL and tacrolimus on levels of donor DNA <I-Ek) in spleens of allogeneic BM recipientsa (experiment 2) 
Treatment Mean densitometry units::,: lSD (median) 
None 240:!:45 (227) 
Tacrolimus 2,965:!:365 (2,882)C 
FL 93:!:19 i89.5)C 
Tacrolimus + FL 29,623:!:3,142 (28,272)d 
a Seven days after BM transplantation (four mice/group). 
b Compared with BM alone. 
e P<0.025 compared with BM alone. 
Donor DNAJlLg % Donor DNA Fold increase in 
total DNA content donor DNAb 
-100 pg 0.01 
-1.2 ng 0.12 12.7 
-38pg 0.004 0.4 
-122 ng 12.2 124.5 
d P<0.025 compared with BM + FL alone using the Mann-Whitney U test. 
TABLE 3. Influence of FL and tacrolimus on spleen weights and cellularity in allogeneic BM recipients (experiment ~F 
Treatment Spleen weight Total nucleated cells (x 106 ) Fold increase in cell (mglg body weight) numbe~ 
None 3.13:!:0.07 85.5:!:8.4 
BM alone 3.71:!:0.15 102.3=:12.5 1.2 
BM +tacrolimus 2.68=:0.OB 6B.5 =: 8.0" O.B 
BM+FL 6.15=:0.99 401.5=:42.zi 4.7 
BM+tacrolimus+FL 6.12=:0.28 324.1=:22.4d 3.B 
a Results are expressed as mean :!: lSD obtained from groups of four mice 7 days after BM transplantation. 
b Compared with normal mice. 
e P<0.05 compared with normal mice. 
d P<O.Ol compared with normal mice. 
TABLE 4. Influence of GM-CSF and FL on donor cell O_Ek+) chimerism in spleens of allogeneic BM recipientga 
I_Ek+ cells/60 high-power Treatment fields 
Experiment 1 
None 1B, 6,21,8 
Tacrolimus 31,75,40,26 
GM-CSF 18, 52, 28, 11 
GM -CSF +tacrolimus 64,64,87,43 
Experiment 2 
None 24,19,14,20 
Tacrolimus 9B,66, 200, 207 
FL 3,0,2,3 
FL+tacrolimus 601, 1025, 374, 796 
a Seven days after BM transplantation (four mice/group). 
b P<0.025 compared with BM alone. 
e P<0.05 compared with BM + cytokine alone. 
d P<0.025 compared with BM + cytokine alone. 
Fold increase 
Mean:!: ISD (Median) in donor MHC 
class II+ cells 
13.3±7.4 (13) 
43.0±22.1 (35.5)b 2.7 
27.3±17.9 (23) 1.B 
64.5±18.0 (64)" 4.9 
19.3±4.1 (19.5) 
142.8:::71.4 (149)b 7.6 
2.0=: 1.4 (2.5)b 0.1 
699±277.4 (69B.5)d .• 35.8 
e P<0.025 compared with BM + tacrolimus alone, using the Mann-Whitney U test. 
mobilize stem and progenitor cells. Because these growth 
factors, e.g., G-CSF, GM-CSF, c-kit ligand (30), IL-3, IL-4, 
IL-8, other C-X-C chemokine family members (31, 32), and 
FL, induce the proliferation of various leukocyte lineages in 
vitro, they are key candidate molecules for the manipulation 
both of donor and recipient BM-derived cells in vivo. Indeed, 
there is evidence that in mice, GM-CSF enhances the effect of 
donor BM cells in prolonging skin allograft survival (33)' 
In the present study, the inf1uence of GM-CSF (a growth 
factor already approved for human use) and the recently 
cloned hematopoietic cytokine FL on short-term chimerism 
in noncytoablated recipients of unmodified allogeneic BM 
was compared. In these immunologically intact hosts, the 
two cytokines alone exhibited opposing effects. Whereas GM-
(SF increased the level of donor DNA and donor MHC class 
II - cells in recipient lymphoid tissue. FL reduced both sub-
,;tantially. In contrast. both cytokmes strikingly augmented 
the level of chimerism when combined with systemic, T cell-
directed immunosuppression (tacrolimus). Remarkably, the 
effect of FL in immunosuppressed recipients was much more 
dramatic than that of GM-CSF, and was associated with a 
much higher incidence and absolute number of donor cells, 
many exhibiting DC characteristics. The quantitative differ-
ences between the systemic effects of GM-CSF and FL on 
donor cell chimerism in immunosuppressed mice are accen-
tuated when account is taken of the pronounced increases in 
absolute numbers of BM-derived cells in lymphoid and non-
lymphoid tissue of FL-treated animals. 
Brasel et al. (2]) have shown recently that in vivo admin-
istration of FL dramatically increases the numbers of hema-
topoietic progenitors in normal mouse BM, blood, and spleen, 
which results in increased myelopoiesis and B lymphopoiesis 
121, 34l. Although FL by itself is only a weak mitogen for 
primitive lineage Sca-l' c-kit - mouse BM progenitors (with 
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FIGURE 1. Identification of donor (BIO.BR1-derived cells (donor 
MHC class II' [I-Ek+ll in spleens of allogeneic (BlO) BM recipients 
7 nays after transplantation ton day 01 and treatment with FL and 
tal'rolimus. Mice were given intravenous injections of 50x 10" un-
m Idied BM cells. and received either FL (10 !J.g/dayl. tacrolimus f~ 
m, kl-(J. or both ul-(ents daily from days 0 to O. Donor MHC class II' 
1 [·l~kD ) cells were detected bv immunohistochemical staininl-( of crv-
ostat sections USIng an aVIdin-biotin-peroxldase procedure I:!.J I, as 
descnbed in .\IatenaLs and !lfethods. Whereas an increase in donor 
dass ll' cells was observed in mIce treated with (AI tucrolimus alone 
compared WIth controls. numbers were reduced substantlallv with 
FL alone I ~ee Table 41. I Bl The combinatIon of FL and tacrohmus 
,;tnkinc;ly mcreased the incIdence of donor cpils. many of whIch t ('1 
,'xhibited morphologic charactenstlcs 01 DC. (,<,lis wpre coUntCf-
,tamed with hematoxvlIn IA. B: " lOO: (': l~llfK 
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FIGURE 2. CTL responses of splenic T cells from normal C3H mice 
and from C3H recipients of allogeneic (BlO) BM 7 days after trans-
plantation. The mice (four per group) received either no treatment, 
FL (10 !J.g/day) alone, FL + tacrolimus (2 mg/kg/day), or tacrolimus 
alone. Results are expressed as mean percent specific target cell lysis 
in triplicate cultures := lSD. 
combined myeloid and lymphoid potentials), it potently pro-
motes in vitro survival of these cells. in part at least, by 
suppressing apoptosis (35, 36). The FL receptor, flt3, is ex-
pressed on pluripotent, long-term reconstituting stem cells 
and early progenitors of the lymphoid myeloid lineages (36, 
37). This population is enriched over 100-fold in the spleens 
ofFL-treated normal mice (38) and at least 20-fold in spleens 
and livers of normal rats given 50 ,.,.g of FL per day for 5 days 
(N. Murase. T. Sakamoto, and A.W. Thomson, unpublished 
observations). The latter findings are consistent with the 
very large increase in FL-responsive, donor-derived cells 
within the spleens of immunosuppressed allogeneic BM re-
cipients observed in the present study. Significantly, FL has 
also been shown to mobilize stem-progenitor cells in nonhu-
man primates (39, 40), highlighting the potential of FL for 
clinical use as a potent hematopoietic growth factor. 
In contrast to GM-CSF, FL reduced the number of donor-
derived cells in spleens of otherwise untreated BM recipients. 
This suggested that FL augmented the host response to 
donor alloantigens. and indeed, we observed augmentation of 
donor-reactive CTL precursors within the spleens of FL-
treated mice. Reversal of this effect by concomitant tacroli-
mus-mediated immunosuppression is consistent with exhibi-
tion of the chimerism-promoting property of FL. The 
apparent ability of FL to augment immune reactivity is in 
keeping with recent observations of its capacity to dramati-
cally increase functional DCs in normal mice (20). to exert 
anti-tumor activity (.J]), and. following donor pretreatment. 
to exacerbate experimental organ allograft rejection (R.J. 
Steptoe et al.. manuscript in preparation I. 
Although DCs are only one of the hematopoietic lineages 
represented in the microchimerism after whole organ trans· 
plantation. and these cells have been Implicated historically 
in the induction of antiallo/.,rraft irnmunitv. DCs also have 
tolerogenic properties lIil. In particular. Des at the "imma-
ture" precursor/progenitor stage mav be capable of subvert-
i ng T-cell responses in VI tro and prolonging allogratt survi val 
'·I:2-.J.J). In addition. there is evidence that a major subpopu-
lation of "lymphOId" Des within normal secondarv lymphOId 
• 
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tissue can suppress responses of allogeneic CD4 + and CD8 + 
T cells by inducing apoptosis (45) or restricting IL-2 produc-
tion (46), respectively. 
The striking increase in allogeneic MHC class II+ cells 
with DC characteristics in immunosuppressed mice treated 
with FL is consistent with the large increase in numbers of 
DCs in spleens and other tissues of FL-treated normal mice 
reported recently by Maraskovsky et al. (20). In contrast to 
the influence of FL, DCs in mouse lymphoid tissue are en-
hanced only to a moderate degree by GM-CSF (20, 47). These 
latter findings include observations on transgenic mice with 
excessive levels of GM-CSF (47). As numbers of both donor 
and host hematopoietic cells of multiple lineages are increased 
by FL administration, there appears to be considerable poten-
tial for this new recombinant growth factor in the investigation 
of the bidirectional immunologic paradigm of tolerance induc-
tion. In particular, it now appears important to ascertain 
the functional significance of the FL-induced augmentation of 
chimerism we have described in organ allograft recipients. 
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